Radioactive Preparation Carriers TRIZ Cases
- EDB-FN Molecular Probes for Precise Tumor Imaging
Targeted peptides linked to MRI, PET, or SPECT contrast agents improve tumor detection specificity while reducing non-specific side effects.
- PSMA Ligand Composition for Tumor Targeting With Lower Salivary Uptake
Novel PSMA ligands improve tumor uptake and retention while reducing salivary gland binding, enabling alpha-radionuclide therapy with less xerostomia.
- Dual-Targeted Cancer Therapeutics With Divergent Biodistribution
Two targeted cancer agents with different biodistribution and pharmacokinetics converge at tumors to boost efficacy without added toxicity.
- Mannosylated Dextran Chelator Conjugation Without Crosslinking
Using a single activated carboxyl group, chelator attachment to amine dextran avoids oligomerization and preserves tilmanocept biodistribution.
- Radiolabeled Luminol Imaging Agents for Non-Invasive ROS Detection
Radiolabeled luminol chelator agents enable non-invasive PET or SPECT imaging of oxidative stress with sensitive ROS detection and stable tissue retention.
- Biocompatible Copolymer Drug Carriers for High-DAR Targeted Delivery
A hydrophilic copolymer enables site-specific, high-DAR drug loading with stable circulation, preserved target affinity, and controlled release.
- Halogenated Somatostatin Analogs for SST2/SST5 Tumor Targeting
Halogen substitution in somatostatin analogs boosts SST2 and SST5 binding while reducing kidney and liver uptake for more specific tumor therapy.
- CD33 Radioconjugates for MDSC Depletion in Breast Cancer
Targeted radioconjugates bind CD33-positive MDSCs and cancer cells to reduce immune escape and strengthen antitumor response in breast cancer.
- FAP-Targeted Cytotoxin Conjugates for Selective Tumor Stroma Therapy
Modular FAP-targeted conjugates localize in tumor stroma and release cytotoxins by enzymatic cleavage to limit healthy tissue damage.
- Granzyme B Imaging Compounds for Immunotherapy Response Assessment
Granzyme B-binding compounds improve immunotherapy response assessment by directly imaging cytotoxic T-cell activity beyond FDG-PET limits.
- F-18 VMAT2 Tracer Precursor With Aromatic-Ring Labeling
Aromatic-ring F-18 labeling avoids F-18-propanol metabolites, lowers organ background, and simplifies VMAT2 PET tracer synthesis.
- Tumor-Targeting NIR Dye Conjugates With Site-Activated Drug Release
Cleavable NIR dye-drug conjugates stay stable in circulation, then release therapy at tumor sites to limit normal-cell toxicity and enable imaging.
- Conductor-Based Radiotracer Delivery for Controlled Biodistribution
A conductor-based trans-vascular approach controls radiotracer biodistribution, reduces off-target exposure, and supports real-time monitored delivery.